Updated Guidance for Homozygous Familial Hypercholesterolemia
A recent report published by The Cardiology Advisor provides updated guidance on managing and treating homozygous familial hypercholesterolemia (HoFH). Homozygous familial hypercholesterolemia is a rare genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of premature cardiovascular disease. The updated guidance emphasizes the importance of early and aggressive treatment to lower LDL-C levels and reduce the risk of cardiovascular events in individuals with HoFH.
The report highlights lipid-lowering therapies, such as statins and PCSK9 inhibitors, combined with other treatment strategies like apheresis and liver transplantation. It also discusses the challenges and limitations associated with managing HoFH, including adherence to treatment regimens and access to specialized care. For more detailed information on the updated guidance for HoFH, please read the full article on The Cardiology Advisor’s website.